Verily opens precision health platform to individual researchers

Individual researchers can now access Verily's precision health platform for free. The company launched self-serve accounts for its Pre platform, giving scientists direct access to biomedical datasets and analysis tools without corporate partnerships.

The move removes barriers that previously limited platform access to large institutions. Researchers get immediate entry to 10 unique datasets plus secure analysis environments through Verily's Exchange and Workbench solutions.

New data sources from RefinedScience, Segmed, and Transcripta will join existing collections from major organizations like the Michael J. Fox Foundation and the National Institutes of Health's All of Us Research Program.

How does it work?

The Standard tier provides free access to Verily's data Exchange and Workbench analysis environment. Researchers can browse datasets, run analyses, and generate insights within secure cloud infrastructure.

Users who need advanced features can upgrade to paid Professional licenses. These accounts allow custom applications, multiple workspaces, and personal data uploads.

The platform handles data security and compliance automatically. Researchers focus on analysis while Verily manages the technical infrastructure behind the scenes.

Why does it matter?

Medical research often stalls because scientists can't access quality datasets or lack proper analysis tools. Verily's platform solves both problems simultaneously.

RefinedScience brings acute myeloid leukemia data that lets researchers ask detailed questions about disease biology. "Researchers can access our high-quality Acute Myeloid Leukemia data pipeline and ask far more granular questions about disease biology and treatment response," said Grant Weller, CTO at RefinedScience.

Segmed adds real-world medical imaging data. CEO David Gascoigne explains: "Advanced imaging data plays a critical role in precision medicine, especially when combined with clinical and other data modalities."

The self-serve model speeds up research timelines. Scientists no longer wait for institutional approvals or lengthy partnership negotiations to access valuable health data.

The context

Precision medicine requires massive datasets to identify patterns and develop targeted treatments. But most researchers lack access to quality biomedical data or secure analysis environments.

Verily's platform addresses this gap by centralizing diverse health datasets in one location. The company combines data from clinical trials, real-world evidence, and specialized research programs.

"These streamlined, self-serve solutions and growing data ecosystem realizes our vision for a unified platform that connects researchers to valuable health data," said Bharat Rajagopal, Verily's Chief Revenue Officer.

The timing aligns with growing demand for AI-driven drug discovery and personalized medicine. Researchers need both quality data and computational power to compete in this space.

Verily positions itself at the intersection of technology and healthcare, offering tools that accelerate evidence generation and enable personalized care at population scale.